Overview

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

Status:
Active, not recruiting

Trial end date:
2021-09-27

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and tolerability of itacitinib in combination with osimertinib in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Incyte Corporation

Collaborator:

AstraZeneca

Treatments:

Osimertinib